【News_EN】
new order | old order
RevolKa announces the closing of ￥250 million series A extension funding to accelerate Drug-Discovery programs
RevolKa Started joint research of a drug discovery program for rare diseases
RevolKa launched a drug discovery program for rare diseases
RevolKa completed the contract research with SEKISUI CHEMICAL CO., LTD
RevolKa Signed Master Service Agreement with Daiichi Sankyo
La Jolla Institute for Immunology and RevolKa started a Research Collaboration
Presentation movie uploaded at Antibody Engineering & Therapeutics 2023
RevolKa raises ￥150 million series A extension
SEKISUI CHEMICAL CO., LTD. and RevolKa Signed a Contract Research Agreement
LATEST ARTICLE
ARCHIVE
- 2025/03 (3)
- 2025/02 (4)
- 2024/11 (1)
- 2024/10 (1)
- 2024/08 (4)
- 2024/07 (4)
- 2024/05 (2)
- 2024/04 (2)
- 2024/03 (1)
- 2024/02 (4)
- 2024/01 (2)
- 2023/12 (2)
CATEGORY
View allTAG